Second Primary Cancers: An Overview

Hematology/Oncology Clinics of North America

Volumn 22, Issue 2, 2008, Pages 271-289

  Ng, Andrea K ^a   Travis, Lois B ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PLATINUM DERIVATIVE; PREDNISONE; PROCARBAZINE; TAMOXIFEN; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER SURVIVOR; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG SUBSTITUTION; EARLY MENOPAUSE; ENDOMETRIUM CANCER; ENVIRONMENTAL FACTOR; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HEREDITY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; MESOTHELIOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SARCOMA; SECOND CANCER; SOLID TUMOR; STOMACH CANCER; TESTIS CANCER; THYROID CANCER; UTERINE CERVIX CANCER; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASMS; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY;

EID: 41549169287     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2008.01.007     Document Type: Review

References (118)

1. Ries L., Melbert D., Krapcho M., et al. SEER cancer statistics review, 1975-2004 (2007), National Cancer Institute, Bethesda (MA)
2. Cancer survivors: living longer, and now, better. Lancet 364 (2004) 2153-2154
3. Dores G., Schonfeld S., Chen J., et al. Long-term cause-specific mortality among 41-146 one-year survivors of Hodgkin lymphoma (HL). Acta Oncologica 23 (2005) 562S
4. Travis L.B. Therapy-associated solid tumors. Acta Oncol 41 (2002) 323-333
5. Travis L.B., Rabkin C.S., Brown L.M., et al. Cancer survivorship-genetic susceptibility and second primary cancers: research strategies and recommendations. J Natl Cancer Inst 98 (2006) 15-25
6. van Leeuwen F.E., and Travis L.B. Second cancers. In: DeVita V.T., Hellman S., Rosenberg S.A., et al. (Eds). Cancer: principles and practice of oncology. 7th edition (2005), Lippincott Williams & Wilkins, Philadelphia 2575-2602
7. Allan J.M., and Travis L.B. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 5 (2005) 943-955
8. Arseneau J.C., Sponzo R.W., Levin D.L., et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med 287 (1972) 1119-1122
9. Cimino G., Papa G., Tura S., et al. Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol 9 (1991) 432-437
10. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 3 Suppl 4 (1992) 117-128
11. Kaldor J.M., Day N.E., Clarke E.A., et al. Leukemia following Hodgkin's disease. N Engl J Med 322 (1990) 7-13
12. Tucker M.A., Coleman C.N., Cox R.S., et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318 (1988) 76-81
13. Valagussa P., Santoro A., Fossati-Bellani F., et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4 (1986) 830-837
14. van Leeuwen F.E., Chorus A.M., van den Belt-Dusebout A.W., et al. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12 (1994) 1063-1073
15. Andrieu J.M., Ifrah N., Payen C., et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 8 (1990) 1148-1154
16. Ng A.K., Bernardo M.V., Weller E., et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100 (2002) 1989-1996
17. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
18. Rueffer U., Josting A., Franklin J., et al. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis. J Clin Oncol 19 (2001) 2026-2032
19. Biti G., Cellai E., Magrini S.M., et al. Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29 (1994) 25-31
20. Doria R., Holford T., Farber L.R., et al. Second solid malignancies after combined modality therapy for Hodgkin's disease. J Clin Oncol 13 (1995) 2016-2022
21. Hodgson D.C., Gilbert E.S., Dores G.M., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25 (2007) 1489-1497
22. Travis L.B., Hill D.A., Dores G.M., et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 290 (2003) 465-475
23. van Leeuwen F.E., Klokman W.J., Stovall M., et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95 (2003) 971-980
24. Travis L.B., Gospodarowicz M., Curtis R.E., et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94 (2002) 182-192
25. Girinsky T., van der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79 (2006) 270-277
26. Swerdlow A.J., Barber J.A., Hudson G.V., et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18 (2000) 498-509
27. Swerdlow A.J., Schoemaker M.J., Allerton R., et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 19 (2001) 1610-1618
28. van Leeuwen F.E., Klokman W.J., Veer M.B., et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (2000) 487-497
29. Aisenberg A.C., Finkelstein D.M., Doppke K.P., et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79 (1997) 1203-1210
30. Sankila R., Garwicz S., Olsen J.H., et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 14 (1996) 1442-1446
31. Bhatia S., Yasui Y., Robison L.L., et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 21 (2003) 4386-4394
32. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 18 (1999) 695-706
33. Gail M.H., Brinton L.A., Byar D.P., et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81 (1989) 1879-1886
34. Travis L.B., Hill D., Dores G.M., et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97 (2005) 1428-1437
35. Mauch P., Ng A., Aleman B., et al. Report from the Rockefeller Foundation sponsored international workshop on reducing mortality and improving quality of life in long-term survivors of Hodgkin's disease: July 9-16, 2003, Bellagio, Italy. Eur J Haematol 75 Suppl (2005) 68-76
36. Andre M., Mounier N., Leleu X., et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood 103 (2004) 1222-1228
37. Mudie N.Y., Swerdlow A.J., Higgins C.D., et al. Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study. J Clin Oncol 24 (2006) 1568-1574
38. Tward J.D., Wendland M.M., Shrieve D.C., et al. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107 (2006) 108-115
39. Freedman D., Curtis R., Travis L., et al. New malignancies following cancer of the uterine corpus and ovary. In: Curtis R., Freedman D., Ron E., et al. (Eds). New malignancies among cancer survivors: SEER cancer registries, 1973-2000 (NIH Publ. No. 05-5302) (2006), National Institutes of Health, Bethesda (MD) 231-255
40. Curtis R.E., Metayer C., Rizzo J.D., et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 105 (2005) 3802-3811
41. Travis L.B., Curtis R.E., Boice Jr. J.D., et al. Second cancers following non-Hodgkin's lymphoma. Cancer 67 (1991) 2002-2009
42. Travis L.B., Gonzalez C.L., Hankey B.F., et al. Hodgkin's disease following non-Hodgkin's lymphoma. Cancer 69 (1992) 2337-2342
43. Travis L.B., Holowaty E., Hunter V., et al. Acute basophilic leukemia and acute eosinophilic leukemia after therapy for non-Hodgkin's lymphoma. Am J Clin Pathol 100 (1993) 186
44. Travis L.B., Curtis R.E., Glimelius B., et al. Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85 (1993) 1932-1937
45. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87 (1995) 524-530
46. Bonnet C., Fillet G., Mounier N., et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 25 (2007) 787-792
47. Shenkier T.N., Voss N., Fairey R., et al. Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. J Clin Oncol 20 (2002) 197-204
48. Schairer C., Hisada M., Chen B.E., et al. Comparative mortality for 621 second cancers in 29,356 testicular cancer survivors and 12,420 matched first cancers. J Natl Cancer Inst 99 (2007) 1248-1256
49. van den Belt-Dusebout A.W., de Wit R., Gietema J.A., et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25 (2007) 4370-4378
50. Travis L.B., Fossa S.D., Schonfeld S.J., et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97 (2005) 1354-1365
51. Fossa S.D., Chen J., Schonfeld S.J., et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 97 (2005) 1056-1066
52. Travis L.B., Andersson M., Gospodarowicz M., et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 92 (2000) 1165-1171
53. Pedersen-Bjergaard J., Daugaard G., Hansen S.W., et al. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 338 (1991) 359-363
54. Kollmannsberger C., Hartmann J.T., Kanz L., et al. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 83 (1999) 860-863
55. Kirova Y.M., Gambotti L., De Rycke Y., et al. Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review. Int J Radiat Oncol Biol Phys 68 (2007) 359-363
56. Gao X., Fisher S.G., and Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys 56 (2003) 1038-1045
57. Hemminki K., Ji J., and Forsti A. Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67 (2007) 868-870
58. Boice Jr. J.D., Harvey E.B., Blettner M., et al. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 326 (1992) 781-785
59. Storm H.H., Andersson M., Boice Jr. J.D., et al. Adjuvant radiotherapy and risk of contralateral breast cancer. J Natl Cancer Inst 84 (1992) 1245-1250
60. Hill-Kayser C.E., Harris E.E., Hwang W.T., et al. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 66 (2006) 1313-1319
61. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
62. Early Breast Cancer Trialists' Collaborative Group (EBDTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
63. Fisher B., Costantino J.P., Redmond C.K., et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. [see comments]. J Natl Cancer Inst 86 (1994) 527-537
64. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. [see comments]. J Natl Cancer Inst 90 (1998) 1371-1388
65. Magriples U., Naftolin F., Schwartz P.E., et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11 (1993) 485-490
66. Bergman L., Beelen M.L., Gallee M.P., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
67. Saadat M., Truong P.T., Kader H.A., et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 110 (2007) 31-37
68. Roychoudhuri R., Evans H., Robinson D., et al. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91 (2004) 868-872
69. Neugut A.I., Robinson E., Lee W.C., et al. Lung cancer after radiation therapy for breast cancer. [see comments]. Cancer 71 (1993) 3054-3057
70. Zablotska L.B., and Neugut A.I. Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma. Cancer 97 (2003) 1404-1411
71. Deutsch M., Land S.R., Begovic M., et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Results of National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trials B-04 and B-06. Cancer 98 (2003) 1362-1368
72. Neugut A.I., Murray T., Santos J., et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. [see comments]. Cancer 73 (1994) 1615-1620
73. Ford M.B., Sigurdson A.J., Petrulis E.S., et al. Effects of smoking and radiotherapy on lung carcinoma in breast carcinoma survivors. Cancer 98 (2003) 1457-1464
74. Huang J., and Mackillop W.J. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer 92 (2001) 172-180
75. Karlsson P., Holmberg E., Samuelsson A., et al. Soft tissue sarcoma after treatment for breast cancer-a Swedish population-based study. Eur J Cancer 34 (1998) 2068-2075
76. Kirova Y.M., Vilcoq J.R., Asselain B., et al. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 104 (2005) 856-863
77. Rubino C., de Vathaire F., Shamsaldin A., et al. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 89 (2003) 840-846
78. Jessner M., Zak F.G., and Rein C.R. Angiosarcoma in postmastectomy lymphedema (Stewart-Treves syndrome). AMA Arch Derm Syphilol 65 (1952) 123-129
79. Esler-Brauer L., Jaggernauth W., and Zeitouni N.C. Angiosarcoma developing after conservative treatment for breast carcinoma: case report with review of the current literature. Dermatol Surg 33 (2007) 749-755
80. Virtanen A., Pukkala E., and Auvinen A. Angiosarcoma after radiotherapy: a cohort study of 332,163 Finnish cancer patients. Br J Cancer 97 (2007) 115-117
81. Simonart T., and Heenen M. Radiation-induced angiosarcomas. Dermatology 209 (2004) 175-176
82. Curtis R.E., Boice Jr. J.D., Stovall M., et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326 (1992) 1745-1751
83. Praga C., Bergh J., Bliss J., et al. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23 (2005) 4179-4191
84. Campone M., Roche H., Kerbrat P., et al. Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Ann Oncol 16 (2005) 1343-1351
85. Park M.J., Park Y.H., Ahn H.J., et al. Secondary hematological malignancies after breast cancer chemotherapy. Leuk Lymphoma 46 (2005) 1183-1188
86. Smith R.E., Bryant J., DeCillis A., et al. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21 (2003) 1195-1204
87. Chen P.Y., and Vicini F.A. Partial breast irradiation. Patient selection, guidelines for treatment, and current results. Front Radiat Ther Oncol 40 (2007) 253-271
88. Liauw S.L., Sylvester J.E., Morris C.G., et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 66 (2006) 669-673
89. Moon K., Stukenborg G.J., Keim J., et al. Cancer incidence after localized therapy for prostate cancer. Cancer 107 (2006) 991-998
90. Kendal W.S., Eapen L., Macrae R., et al. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer. Int J Radiat Oncol Biol Phys 65 (2006) 661-668
91. Chrouser K., Leibovich B., Bergstralh E., et al. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174 (2005) 107-110 [discussion: 110-11]
92. Hall E.J., and Wuu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56 (2003) 83-88
93. Pickles T., and Phillips N. The risk of second malignancy in men with prostate cancer treated with or without radiation in British Columbia, 1984-2000. Radiother Oncol 65 (2002) 145-151
94. Brenner D.J., Curtis R.E., Hall E.J., et al. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88 (2000) 398-406
95. Neugut A.I., Ahsan H., Robinson E., et al. Bladder carcinoma and other second malignancies after radiotherapy for prostate carcinoma. Cancer 79 (1997) 1600-1604
96. Guckenberger M., and Flentje M. Intensity-modulated radiotherapy (IMRT) of localized prostate cancer: a review and future perspectives. Strahlenther Onkol 183 (2007) 57-62
97. Kry S.F., Salehpour M., Followill D.S., et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 1195-1203
98. Kleinerman R.A., Curtis R.E., Boice Jr. J.D., et al. Second cancers following radiotherapy for cervical cancer. J Natl Cancer Inst 69 (1982) 1027-1033
99. Kleinerman R.A., Boice Jr. J.D., Storm H.H., et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer 76 (1995) 442-452
100. Boice Jr. J.D., Engholm G., Kleinerman R.A., et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 116 (1988) 3-55
101. Boice Jr. J.D., Blettner M., Kleinerman R.A., et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79 (1987) 1295-1311
102. Chaturvedi A.K., Engels E.A., Gilbert E.S., et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 99 (2007) 1634-1643
103. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
104. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
105. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
106. Poirier M.C., Reed E., Litterst C.L., et al. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 52 (1992) 149-153
107. Greene M.H. Is cisplatin a human carcinogen?. J Natl Cancer Inst 84 (1992) 306-312
108. Travis L.B., Holowaty E.J., Bergfeldt K., et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 340 (1999) 351-357
109. Leon X., Ferlito A., Myer III C.M., et al. Second primary tumors in head and neck cancer patients. Acta Otolaryngol 122 (2002) 765-778
110. Gallo O., Sardi I., Pepe G., et al. Multiple primary tumors of the upper aerodigestive tract: is there a role for constitutional mutations in the p53 gene?. Int J Cancer 82 (1999) 180-186
111. Cianfriglia F., Di Gregorio D.A., and Manieri A. Multiple primary tumours in patients with oral squamous cell carcinoma. Oral Oncol 35 (1999) 157-163
112. Leon X., Quer M., Diez S., et al. Second neoplasm in patients with head and neck cancer. Head Neck 21 (1999) 204-210
113. Rinaldo A., Marchiori C., Faggionato L., et al. The association of cancers of the larynx with cancers of the lung. Eur Arch Otorhinolaryngol 253 (1996) 256-259
114. Berg J.W., Schottenfeld D., and Ritter F. Incidence of multiple primary cancers. III. Cancers of the respiratory and upper digestive system as multiple primary cancers. J Natl Cancer Inst 44 (1970) 263-274
115. Day G.L., Blot W.J., Shore R.E., et al. Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J Natl Cancer Inst 86 (1994) 131-137
116. Bongers V., Braakhuis B.J., Tobi H., et al. The relation between cancer incidence among relatives and the occurrence of multiple primary carcinomas following head and neck cancer. Cancer Epidemiol Biomarkers Prev 5 (1996) 595-598
117. Jain S., Khuri F.R., and Shin D.M. Prevention of head and neck cancer: current status and future prospects. Curr Probl Cancer 28 (2004) 265-286
118. Smith W., and Saba N. Retinoids as chemoprevention for head and neck cancer: where do we go from here?. Crit Rev Oncol Hematol 55 (2005) 143-152